Expert opinion: A large number of potential risk factors have been identified in recent studies. However, there is a lack of consensus, and many of the suggested risk factors have not been rigorously validated in independent studies. There is a need for largescale, prospective studies to consolidate existing findings and discover new risk factors.
Introduction
Non-Hodgkin Lymphoma (NHL) is a heterogeneous group of malignancies of lymphocyte origin. NHL usually arises or is present in lymphoid tissues, such as lymph nodes, spleen and bone marrow. During the past three decades, there have been consistent reports of increase in the incidence of NHL worldwide. In general, ageadjusted incidence rates of NHL are higher in more developed countries. In the United States, the age-adjusted incidence rate has almost doubled since the 1970s from 11.07/100,000 in 1975 to 20.20/100,000 in 2008 [1] . It is the fifth most commonly diagnosed malignancy in the US among both men and women. According to the National Cancer Institute, it is estimated that 66,360 new cases of NHL were diagnosed in 2011, with 19,320 deaths. The Lymphoma Research Foundation estimates that 332,000 Americans are currently living with NHL. There are over thirty NHL subtypes, with the two most common subtypes -diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) -accounting for about 30% and 20% of all NHL cases, respectively [2] .
FL is defined as a lymphoma of follicle center B-cells, which has at least a partially follicular pattern [2] . It is positive for the B-cell markers CD10, CD19, CD20 and CD22, but almost always negative for CD5. It is the most common form of indolent NHL.
According to the WHO criteria, FL can be morphologically graded into grade 1 (<5 3 centroblasts per high-power field (hpf)), grade 2 (6-15 centroblasts/hpf) and grade 3 (>15 centrobalsts/hpf). Grade 3 can be further subdivided into grade 3A (centrocytes still present) and grade 3B (the follicles consist almost entirely of centroblasts). Grades 1, 2, and 3A are considered to be indolent and incurable, whereas grade 3B is considered an aggressive but curable disease similar to DLBCL. It has been noted that although this grading system is valuable from a pathological perspective, its clinical relevance is still debatable. Over time, histologic transformation of FL from an indolent disease to a DLBCL may occur in 10-70% of patients, with an estimated risk of 3% per year, and is associated with rapid progression of lymphadenopathy, extranodal disease, B symptoms and elevated serum LDH [3] . FL may also transform to Burkitt lymphoma or other types of aggressive lymphomas, although much less commonly.
Compared with some other forms of NHL, for example DLBCL, FL usually progresses slowly. Despite the fact that most FLs are advanced at the time of diagnosis, the median survival of patients with FL is approximately 8-10 years, and many patients may not require treatment for a long time. Several retrospective studies have shown an important improvement in overall survival of FL patients in the last fifteen years when compared to historical controls. The improvement has been largely attributed to the introduction of anti-CD20 monoclonal antibodies (MoAba) in the treatment [4] .
Considerable effort has been devoted to the identification of NHL risk factors [5] .
In this article, we focus on FL and refer to other publications for discussions on other types of NHL. "Classic" research on FL risk factors has been focused on clinical measurements and environmental exposures. More recently, with the fast development of high-throughput profiling techniques, genome-wide analysis has been extensively 4 conducting using various platforms including gene expression profiling, array comparative genomic hybridization (aCGH), single nucleotide polymorphisms (SNP) arrays and several other novel technologies that measure methylation status and epigenome. In the following sections, we review risk factors identified for FL etiology and prognosis separately. For each aspect, clinical measurements, environmental exposures, and omics risk factors are reviewed. In addition, we also provide brief discussions on several pitfalls in the pursuit of FL risk factors. We acknowledge that the identification of FL risk factors is an extremely complex process, involving a large number of steps including study design, execution, analysis, validation and others. Due to the limited scope of this article, inevitably, some important aspects will be missed. We refer to [5, 6, 7] and references therein for related discussions.
Etiology

Clinical and environmental risk factors
Overall, the etiology of NHL is poorly understood [5] . It has been suggested that age, gender, and ethnicity may affect a person's likelihood of developing FL. The incidence of FL increases with age. Although in principal FL may occur at any age, it is extremely rare in children. The median age at diagnosis is 60-65 years. Women have a slightly higher risk of developing FL than men. The incidence of FL is low among Chinese and Japanese. People of Jewish ancestry have a higher incidence of lymphoma. In the US, the incidence is 2-3 times higher in Caucasian than in African-American.
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Risk factors that may increase the risk of NHL also include medications that suppress the immune system (for example if a person has just had an organ transplant, he/she is more susceptible because immunosuppressive therapy has reduced the body's ability to fight off new illnesses), and infection with certain viruses and bacteria.
Viruses that have been implicated in the development of FL include the Epstein-Barr virus (EBV), human T-cell lymphotropic virus (HTLV) type I, and the herpesvirus associated with Kaposi sarcoma (i.e., human herpesvirus HHV-8) [8] . It is worth pointing out that although they have been implicated in the development of FL, these viruses are Certain chemicals, such as those used to kill insects and weeds, may increase the risk of developing NHL. An increased risk of FL was found among women who started using hair dyes before 1980, and cannot be excluded for women who started using in 1980 and after [9] . However, more research is needed to better understand the mechanical link between pesticides and the development of FL.
Multiple lifestyle factors may also contribute to the risk of FL. However, it is noted that some conflicting results have been reported in the literature. A case-control study conducted in Italy has linked tobacco use to the development of FL [10] . The researchers reported a 50% increased risk for 16-33 pack-years to an 80% increased risk with 34 pack years or greater. There was no increased risk for the other NHL subtypes. In a second study, analysis of data on over 6,500 NHL cases also suggested 6 a positive link between smoking and incidence of FL but not other NHL subtypes. United
States researchers from Yale University have reported that long-term cigarette smoking in women increased the risk of developing FL [13] . Analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which had 1,264 histologically confirmed NHL cases, suggested that smoking was not associated with NHL overall but was inversely associated with FL (ever smoking vs never: hazard ratio(HR)=0.62, 95% confidence interval [0.45, 0.85]) [12] . Alcohol intake may directly affect immune function, which is an important etiologic factor for lymphoid malignancies. Morton and others [13] conducted a pooled analysis of nine case-control studies of NHL and showed that ever drinkers, compared with never drinkers, had a 17% lower risk of NHL. This finding can be potentially explained by a beneficial effect of moderate alcohol consumption on immune system. However, no significant dose-response relationship was observed, which could be used to argue against a possible biological mechanism for the observed inverse association. Analysis of the PLCO data suggested that alcohol consumption was unrelated to NHL (drinks/week: p-value for trend=0.187) [12] . In six large prospective cohort studies of alcohol and NHL, researchers found that moderate alcohol intake was associated with a 41% reduction in risk among Iowa women, and heavier alcohol intake was associated with a 33% risk reduction among United Kingdom women, a 23% risk reduction among retired US men and women, and a 40% reduction among Japanese men. However, alcohol intake was not associated with NHL risk among Finnish male smokers or US men and women in a cancer screening trial. Chang and others [14] [15] . In a prospective cohort study with 37,931 Iowa women among whom there were 261 cases of NHL and 58 cases of FL, Cerhan and others [16] observed no overall association between anthropometric characteristics (including BMI) and risk of overall NHL or FL. In contrast, in a population-based case-control study, Skibola and others [17] found that the risks of NHL and FL were positively associated with an overweight or obese status compared to a normal-weight status. In a Scandinavian study with 3,055 NHL cases and 3,187 population-based controls, Cheng and others did not find any association between BMI and risk of FL [18] .
Omics risk factors
As with other types of cancers and other subtypes of NHL, there is increasing evidence that omics (genetic, genomic, epigenetic…) risk factors may have independent contribution to the risk of FL beyond clinical risk factors and environmental exposures [5, 19, 20, 21] . 8 The most common acquired nonrandom chromosomal translocation in FL patients is the t(14; 18) translocation, which is found in more than 80% of all cases. This translocation results in the overexpression of the BCL-2 gene, which encodes apoptosis regulator proteins and has been implicated in a number of cancers including melanoma, breast, prostate and lung carcinomas. In fact, the detection of the t(14, 18) product by polymerase chain reaction (PCR) has been frequently used in the diagnosis and followup of patients with FL. In some cases, the presence of BCL-2 staining in biopsies may be significant for the patient's prognosis or likelihood of relapse. However, this translocation is not unique to FL. It has been detected in healthy patients as well as patients with other types of tumors. A small fraction of FL (~5%) does not exhibit the classical t(14;18) but instead contains alterations affecting BCL-6 at 3q27, including t(3;14)(q27;q32) [22] . This leads to deregulated expression of the transcriptional repressor BCL-6, which is normally required for germinal centers formation. Protein Conde and others [25] conducted a three-stage genome-wide association study and identified two variants associated with FL at 6q21.32 (rs10484561 and rs7755224).
The combined sample contained 1,465 FL cases and 6,011 controls. For rs10484561, the combined OR (odds ratio) was 1 p14 protein is also a cyclin-dependent kinase inhibitor known to induce cell cycle arrest at G1 and G2. Mice with homozygous deletion of p14 frequently develop numerous tumors including lymphomas. Despite interesting findings in animal studies, Baur and others [35] failed to find methylation of the p14 promoter region in FL samples.
Hypermethylation of p14 does not appear to be a common epigenetic event in FL. As suggested in [27] , genes whose methylation may be involved in FL etiology also include GSTP1, IL-12 receptor beta-2, Snk/plk2 and GADD45-gamma. More research is needed to draw definitive conclusion on these genes.
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Prognosis
FLIPI and FLIPI2
The prognosis of FL has attracted extensive attention. [43] were among the first to test the hypothesis that a higher intake of fruits and vegetables is associated with better NHL survival [44] . Using a population-based cohort of 568 women with newly diagnosed NHL followed for a median of 7.7 years, the researchers found 32% better overall survival for NHL patients who had higher pre- 
Omics risk factors
Dave and others [45] Five out of the 12 cases displayed enhanced expression of C-MYC and its target genes, whereas in four cases a decreased expression of C-MYC and its target genes was observed. De Vos and others [49] profiled four FLs with documented progressions.
Among the top 36 up-regulated and 36 down-regulated genes, seven genes were also identified by [48] . Genes CDA and GAPD, two genes reflecting levels of metabolism, were among the overlapped and up-regulated. Genes IRF8 and of PTPRC were also Studies have linked 1p36 deletions with worse prognosis in FL [56] . With a cohort consisting of 251 specimens, the researchers identified 46 cases with nonsynonymous mutations affecting TNFRSF14 (tumor necrosis factor receptor superfamily member 14).
OS and disease-specific survival (DSS) were associated with the present of TNFRSF14 mutation in patients whose overall treatment included rituximab. It was further shown that inferior OS and DSS were most pronounced in patients whose lymphomas contained both TNFRSF14 mutations and 1p36 deletions after adjustment for FLIPI.
O'Shea and others [57] studied 185 FL patients to assess the prognostic relevance of aUPD (acquired homozygosity in the form of segmental acquired uniparental disomy). It was found that the number of genetic abnormalities was predictive of outcome. In particular, the presence of more than three abnormalities was associated with inferior OS. Sites of recurrent aUPD were detected on 6p, 16p, 12q, 1p36, 10q and 6q. In multivariate analysis, aUPD on 1p36 correlated with shorter OS.
aUPD on 16p was predictive of transformation and correlated with poorer PFS.
With its important implications in the etiology of FL, methylation was also investigated as potential risk factors for prognosis [58] . It was found that methylation 
Discussion
Identification of FL risk factors is of significant interest. In cancer study overall, it is estimated that one-third of cancer occurrences are preventable, and that one-third of people with cancer can recover fully if the cancer is detected at an early stage.
Identifying risk factors contributing to FL etiology can help specify high risk population and facilitate preventive actions. FL is an indolent disease. For many patients, a "watch and wait" strategy may be sufficient [59, 60] . Thus, it is important to single out patients possibly with an aggressive path for active treatment. Some recent studies such as [5] investigate NHL overall. Different subtypes of NHL, although sharing a certain degree of similarity, differ significantly from each other. From a practical point of view, it is necessary to study each subtype separately. 
Expert opinion
In the literature, a large number of possible FL risk factors have been suggested, some of which are reviewed in this article. Unfortunately, many of them have low reproducibility and have not been successfully validated in independent studies. As discussed in [5, 63] as discussed in a recent study [5] , existing analytic techniques for omics data have limitations, and there is a need for more effective analysis methods.
As with other subtypes of NHL and other cancers, the development and progression of FL is a complex process and involves the interactions of multiple clinical risk factors, environmental exposures, genetic, genomic, epigenetic events and others.
Most existing studies and analysis approaches only target a subset of potential risk factors, which may result in biased estimates and false risk factor identification. For some cancers, there are studies attempting to systematically investigate and integrate a large number of different types of risk factors. However, to the best of our knowledge, there is still no such study on FL.
In several prognosis studies, the FLIPI has been shown to be effective. Similar success has been observed for a few other risk factors/indexes. However, it has been noted that these risk factors are only effective at a population level, predicting "average" risk and progression for a group of subjects. The prediction accuracy for a single subject 23 has been disappointingly low. In recent cancer research, a lot of attention has been devoted to personalized medicine, with the ultimate goal of predicting cancer development and progression at an individual level. For FL, there is insufficient attention on personalized predictive modeling and risk factor identification.
Our recommendations for future research include the following. First, existing literature needs to be more carefully and more systematically examined. Risk factors suggested in multiple studies warrant a higher priority in future validation studies. In addition, it is of significant interest to examine the causes of discrepancies (in the identified risk factors). The differences between cohorts' characteristics and technical aspects (such as platforms and profiling protocols in omics studies) need to be quantified. Such examination may help determine how much discrepancy can be attributed to heterogeneity among studies and improve reproducibility of identified risk factors. Second, it is worthwhile to reanalyze existing studies, particularly omics studies, using more advanced analytic methods. For example, in most published gene expression and SNP studies, the interplay among genes is not sufficiently accounted for. There is a need to reanalyze such data using methods that take a system biology point of view. We refer to [5] for more detailed discussions. Third, there is a need for carefully-designed, prospective studies that comprehensively collect information on multiple types of risk factors. The International Lymphoma Epidemiology Consortium (InterLymph) may serve as a prototype for such studies.
Article Highlights
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• Follicular lymphoma is the second most common subtype of NHL and the most common indolent one.
• Despite a significant amount of effort, the etiology and prognosis of FL remain poorly understood.
• A large number of potential risk factors have been suggested in the literature.
However, there is a lack of consensus, and many suggested risk factors have not been rigorously validated in independent studies.
• More studies are needed to consolidate the existing findings and discover more FL risk factors. There is also need for research on personalized risk factors.
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